Skip to main content

Advertisement

SpringerLink
Log in

Kidney cancer

mTOR or VEGFR inhibition—get the order right

  • Research Highlight
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Motzer, R. J. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 10.1200/JCO.2013.54.6911

Download references

Authors
  1. Mina Razzak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Razzak, M. mTOR or VEGFR inhibition—get the order right. Nat Rev Urol 11, 488 (2014). https://doi.org/10.1038/nrurol.2014.198

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.198

  • Springer Nature Limited

Search

Navigation